Showing results (91-100 of 119) with videos related to
Sort By:
Pageof 12
European Journal of Heart Failure|May 22, 2012
Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)David Preiss, Dirk J van Veldhuisen, Naveed Sattar, et al.Bioengineering (Basel, Switzerland)|February 26, 2025
Applications of Machine Learning-Driven Molecular Models for Advancing Ophthalmic Precision MedicineRahul Kumar, Joshua Ong, Ethan Waisberg, et al.European Journal of Heart Failure|February 16, 2019
Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trialJoão Pedro Ferreira, Paula Abreu, John J V McMurray, et al.European Journal of Heart Failure|February 3, 2016
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF studyKen Lee Chin, Timothy J Collier, Bertram Pitt, et al.European Journal of Heart Failure|July 4, 2015
Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF)Jane A Cannon, Timothy J Collier, Li Shen, et al.Circulation. Heart Failure|December 4, 2013
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)Patrick Rossignol, Daniela Dobre, John J V McMurray, et al.Diabetes, Obesity & Metabolism|March 20, 2024
Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regressionFrederick Berro Rivera, Grace Nooriza O Lumbang, Danielle Rose Magno Gaid, et al.JACC. Advances|January 29, 2025
Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a): A Meta-Analysis and Meta-Regression of Randomized Controlled TrialsFrederick Berro Rivera, Sung Whoy Cha, Cruz Linnaeus Louisse, et al.Journal of Hypertension|October 5, 2019
Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trialLuca Monzo, João Pedro Ferreira, Paula Abreu, et al.Clinical Research in Cardiology : Official Journal of the German Cardiac Society|August 31, 2017
Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER StudyJoão Pedro Ferreira, Kévin Duarte, Gilles Montalescot, et al.Pageof 12